Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity (2016 - 2025)
Organogenesis Holdings has reported Liabilities and Shareholders Equity over the past 10 years, most recently at $598.7 million for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $598.7 million for Q4 2025, up 20.25% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 10.36% YoY), and the annual figure for FY2025 was $598.7 million, up 20.25%.
- Liabilities and Shareholders Equity for Q4 2025 was $598.7 million at Organogenesis Holdings, up from $509.8 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for ORGO hit a ceiling of $598.7 million in Q4 2025 and a floor of $319.2 million in Q1 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $453.3 million (2022), compared with a mean of $449.5 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 64.24% in 2021 and later dropped 3.53% in 2024.
- Organogenesis Holdings' Liabilities and Shareholders Equity stood at $443.3 million in 2021, then rose by 1.38% to $449.4 million in 2022, then rose by 2.37% to $460.0 million in 2023, then increased by 8.23% to $497.9 million in 2024, then rose by 20.25% to $598.7 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $598.7 million (Q4 2025), $509.8 million (Q3 2025), and $461.1 million (Q2 2025) per Business Quant data.